Valganciclovir: What is the Status in Solid Organ Transplantation?

Abstract

Prophylactic drug therapy for cytomegalovirus disease in solid organ transplant recipients is effective and simple to implement, but it is associated with patient nonadherence and viral resistance. Recent data show that the efficacy and safety of oral ganciclovir and oral valganciclovir are similar. However, three large daily doses of oral ganciclovir are required, which is inconvenient, and viral resistance can develop to the drug. The single daily dose and lack of viral resistance are advantages of valganciclovir. This has become the primary agent for the prevention of cytomegalovirus disease. Current trials are underway to determine its effectiveness for treatment of cytomegalovirus disease, the optimal length of prophylaxis, and the safety and efficacy of a syrup formulation in children.